{"celex_id": "32005D0171", "uri": "http://publications.europa.eu/resource/cellar/0b86481a-3349-4cca-a1de-c02666bc0bcc", "type": "Decision", "concepts": ["2739", "3591", "4308", "535", "5798"], "title": "2005/171/EC: Commission Decision of 23 February 2005 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2004 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2005) 293) (Text with EEA relevance)\n", "header": "2.3.2005 EN Official Journal of the European Union L 56/25\nCOMMISSION DECISION\nof 23 February 2005\non the allocation of quantities of controlled substances allowed for essential uses in the Community in 2004 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council\n(notified under document number C(2005) 293)\n(Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Portuguese, Slovenian and Spanish texts are authentic)\n(Text with EEA relevance)\n(2005/171/EC)\nTHE COMMISSION OF THE EUROPEAN COMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Community,\nHaving regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer\u00a0(1), and in particular Article 3(1) thereof,\nWhereas:\n(1) The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride,1,1,1-trichloroethane, hydrobromofluorocarbon and bromo-chloromethane.\n(2) Each year the Commission has to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.\n(3) Decision IV/25 of the Parties to the Montreal Protocol on substances that deplete the ozone layer, hereinafter \u2018the Montreal Protocol\u2019, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.\n(4) Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the sixth Meeting of the Parties, Decision VII/11 and Decision XI/15 of the Parties to the Montreal Protocol.\n(5) Pursuant to paragraph 3 of Decision XII/2 of the 12th Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Luxembourg, Norway, Portugal, the Netherlands, Sweden and the United Kingdom have notified the United Nations Environment Programme\u00a0(2) that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of specific short-acting beta agonist CFC-MDIs. Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have reduced the demand for CFCs in the Community. In addition, Article 4(6) prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).\n(6) The Commission published a notice\u00a0(3) on 11 July 2003 to those companies in the Community (15) that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2004 and a further notification to companies in the 10 new Member States on 11 May 2004\u00a0(4), and has received declarations on intended essential uses of controlled substances in 2004.\n(7) Commission Decision 2004/209/EC of 28 January 2004 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2004 pursuant to Regulation (EC) No 2037/2000 of the European Parliament and of the Council\u00a0(5) should be amended in order to take account of the inclusion of specific quantities of ozone depleting substances required for essential uses in the 10 new Member States from 1 May 2004.\n(8) In the interests of legal clarity and transparency Decision 2004/209/EC should therefore be replaced.\n(9) The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,", "main_body": ["1.\u00a0\u00a0\u00a0The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2004 shall be 1\u00a0428\u00a0533,000 ODP (ozone depletion potential) kilograms.\n2.\u00a0\u00a0\u00a0The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2004 shall be 73\u00a0336,765 ODP kilograms.\n3.\u00a0\u00a0\u00a0The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2004 shall be 19\u00a0268,700 ODP kilograms.\n4.\u00a0\u00a0\u00a0The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2004 shall be 141\u00a0834,000 ODP kilograms.\n5.\u00a0\u00a0\u00a0The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2004 shall be 529,300 ODP kilograms.\n6.\u00a0\u00a0\u00a0The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2004 shall be 3,070 ODP kilograms.\n7.\u00a0\u00a0\u00a0The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2004 shall be 13,248 ODP kilograms.", "The chlorofluorocarbon metered-dose inhalers (CFC-MDIs) listed in Annex I shall not be placed on markets that have determined CFCs for these products to be non-essential.", "During the period 1 January to 31 December 2004 the following rules shall apply:\n1. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.\n2. The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.\n3. The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.\n4. The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.\n5. The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.\n6. The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VII.\n7. The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex VIII.\n8. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex IX.", "Decision 2004/209/EC is repealed.\nReferences to the repealed Decision shall be construed as references to this Decision.", "This Decision is addressed to the following undertakings:\n3M Health Care Ltd\n3M House Morley Street\nLoughborough\nLeicestershire LE11 1EP\nUnited Kingdom\nAventis\nLondon Road, Holmes Chapel\nCheshire CW4 8BE\nUnited Kingdom\nBespak PLC\nNorth Lynn Industrial Estate\nKing's Lynn\nNorfolk PE30 2JJ\nUnited Kingdom\nBoehringer Ingelheim GmbH\nBinger Strasse 173\nD-55216 Ingelheim am Rhein\nChiesi Farmaceutici SpA\nVia Palermo 26/A\nI-43100 Parma\nGlaxoSmithKline\nSpeke Boulevard\nSpeke\nLiverpool L24 9JD\nUnited Kingdom\nIG Spr\u00fchtechnik GmbH\nIm Hemmet 1\nD-79664 Wehr\nInyx Pharmaceuticals Ltd\nAstmoor Industrial Estate\n9 Arkwright Road Runcorn\nCheshire WA7 1NU\nUnited Kingdom\nIVAX Ltd\nUnit 301 Industrial Park\nWaterford\nIreland\nJaba Farmaceutica SA\nRua da Tapada Grande, 2\nP-2710-089, Abrunheira Sintra\nLaboratorio Aldo Union SA\nBaronesa de Mald\u00e1 73\nEspluges de Llobregat\nE-08950 Barcelona\nOtsuka Pharmaceuticals (E)\nProvenca, 388\nE-08025 Barcelona\nSICOR SpA\nVia Terrazzano 77\nI-20017 RHO Milano\nSchering-Plough Labo NV\nIndustriepark 30\nB-2220 Heist Op Den Berg\nValvole Aerosol Research Italiana\n(VARI) Spa \u2014 LINDAL Group Italia\nVia del Pino, 10\nOlginate (LC)\nI-23854 Italia\nValeas SpA Pharmaceuticals\nVia Vallisneri, 10\nI-20133 Milano\nValois SA\n50 avenue de l\u2019Europe\nF-78160 Marly-Le-Roi\nAcros Organics bvba\nJanssen Pharmaceuticalaan 3a\nB-2440 Geel\nAirbus France\n316, route de Bayonne\nF-31300 Toulouse\nAgfa-Gevaert NV\nSeptestraat 27\nB-2640 Mortsel\nBie & Berntsen\nSandb\u00e6kvej 7\nDK-2610 R\u00f8dovre\nBiosolove BV\nWaalreseweg 17\n5554 HA Valkenswaard\nThe Netherlands\nButterworth Laboratories Ltd\n54 Waldegrave Road, Teddington\nMiddlesex TW11 8NY\nUnited Kingdom\nCarl Roth GmbH\nSchoemperlenstr. 1\u20145\nD-76185 Karlsruhe\nElcom Group\nOkru\u017en\u00ed 988\nCZ-735 14 Orlov\u00e1 \u2014 Lutyn\u011b\nEnvironnement SA\n111, Bld Robespierre\nBP 4513\nF-78304 Poissy\nFisher Scientific\nBishop Meadow Road\nLoughborough LE11 5RG\nUnited Kingdom\nHealth Protection Inspectorate-Laboratories\nPaldiski mnt 81\nEE-10617 Tallinn\nHoneywell Specialty Chemicals\nWunstorfer Stra\u00dfe 40\nPostfach 100262\nD-30918 Seelze\nInstitut scientifique de service public (ISSeP)\nRue du Ch\u00e9ra 200\nB-4000 Li\u00e8ge\nInstitut E. Malvoz (B)\nQuai du Barbou, 4\nB-4000 Li\u00e8ge\nIneos Fluor Ltd\nPO Box 13, The Heath\nRuncorn Cheshire WA7 4QF\nUnited Kingdom\nKatholieke Universiteit Leuven\nKrakenstraat 3\nB-3000 Leuven\nLaboratoires s\u00e9robiologiques\n3, rue de Seichamps\nF-54425 Pulnoy\nLGC Promochem GmbH\nMercatorstr. 51\nD-46485 Wesel\nMallinckrodt Baker BV\nTeugseweg 20\n7418 AM Deventer\nThe Netherlands\nMerck KgaA\nFrankfurter Strasse 250\nD-64271 Darmstadt\nMikro+Polo d.o.o.\nLackova 78\nSLO-2000 Maribor\nPanreac Qu\u00edmica SA\nRiera de Sant Cugat 1\nE-08110 Montcada I Reixac (Barcelona)\nRohs Chemie GmbH\nBerliner Str. 54\nD-53819 Neunkirchen-Seelsheid\nSanolabor d.d.\nLesko\u0161kova 4\nSLO-Ljubljana\nSDS Solvants, Documentation, Synth\u00e8ses SA\nZ.I. de Valdonne, BP 4\nF-13124 Peypin\nSigma Aldrich Chemie GmbH\nRiedstrasse 2\nD-89555 Steinheim\nSigma Aldrich Chimie SARL\n80 rue de Luzais\nL'Isle-d'Abeau Chesnes\nF-38297 St-Quentin-Fallavier\nSigma Aldrich Company Ltd\nThe Old Brickyard\nNew Road Gillingham SP8 4XT\nUnited Kingdom\nSigma Aldrich Laborchemikalien\nWunstorfer Stra\u00dfe 40, Postfach 100262\nD-30918 Seelze\nVWR I.S.A.S.\n201, rue Carnot\nF-94126 Fontenay-sous-bois\nUniversity Of Technology Vienna\nInstitut of Industrial Electronics and Material Science\nGusshausstrasse 27-29\nA-1040 Wien\nYA-Kemia Oy \u2014 Sigma-Aldrich Finland\nTeerisuonkuja 4\nFI-00700 Helsinki"], "attachments": "Done at Brussels, 23 February 2005.\nFor the Commission\nStavros DIMAS\nMember of the Commission\n(1)\u00a0\u00a0OJ L 244, 29.9.2000, p. 1. Regulation as last amended by Commission Regulation (EC) No 2077/2004 (OJ L 359, 4.12.2004, p. 28).\n(2)\u00a0\u00a0www.unep.org/ozone/dec12-2-3.shtml\n(3)\u00a0\u00a0OJ C 162, 11.7.2003, p. 19.\n(4)\u00a0\u00a0OJ C 133, 11.5.2004, p. 12.\n(5)\u00a0\u00a0OJ L 66, 4.3.2004, p. 36.\nANNEX I\nPursuant to paragraph 3 of Decision XII/2 of the 12th Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following Parties have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as \u2018essential\u2019 under the Protocol when combined with following products:\nProduct Salbutamol Terbutaline Fenoterol Orciprenaline Reproterol Carbuterol Hexoprenaline Pirbuterol Clenbuterol Bitolterol Procaterol Beclomethasone Dexamethasone Fluinisolide Fluiticasone Budesonide Triamcinolone Ipratropium bromide Oxitropium Bromide\nAustria X X X X X X X X X X X\nBelgium X X X X X X X X X X X\nCzech Republic X X X X X X X X X X X\nDenmark X X X X X X X X X X X\nFinland X\nFrance X\nGermany X X X X X X X X X X X X X X X X X X X\nGreece X X X X X X X X X X X\nIreland X\nLuxembourg X\nPortugal X X X X X X X X X X X\nThe Netherlands X X X X X X X X X X X\nNorway X X X X X X X X X X X\nSweden X\nUK X\nSource: www.unep.org/ozone/dec12-2-3.pdf\nANNEX II\nESSENTIAL MEDICAL USES\nQuota of controlled substances of Group I that may be used in the production of metered-dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:\n3M (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nAventis (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBespak (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBoehringer Ingelheim (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nChiesi (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nGlaxo Smith Kline (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIG Spr\u00fchtechnik (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nInyx Pharmaceuticals (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIVAX (IE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nJaba Farmaceutica (PT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nLab. Aldo-Union (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nOtsuka Pharmaceuticals (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSicor (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSchering-Plough (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nV.A.R.I. (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nValeas (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nValois (FR)\n3M (UK)\nAventis (UK)\nBespak (UK)\nBoehringer Ingelheim (DE)\nChiesi (IT)\nGlaxo Smith Kline (UK)\nIG Spr\u00fchtechnik (DE)\nInyx Pharmaceuticals (UK)\nIVAX (IE)\nJaba Farmaceutica (PT)\nLab. Aldo-Union (ES)\nOtsuka Pharmaceuticals (ES)\nSicor (IT)\nSchering-Plough (BE)\nV.A.R.I. (IT)\nValeas (IT)\nValois (FR)\nANNEX III\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:\nAgfa-Gevaert (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBie & Berntsen (DK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nButterworth Laboratories (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBiosolve (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nCarl Roth (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nElcom Group (CZ)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nEnvironnement SA (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nHoneywell Specialty Chemicals (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nKatholieke Universiteit Leuven (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nLGC Promochem (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMallinckrodt Baker (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMerck KGaA (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMikro + Polo (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nPanreac Qu\u00edmica (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSDS Solvants (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSanolabor (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nUniversity Of Technology Vienna (AT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nYa Kemia Oy \u2014 Sigma Aldrich (FI)\nAgfa-Gevaert (BE)\nBie & Berntsen (DK)\nButterworth Laboratories (UK)\nBiosolve (NL)\nCarl Roth (DE)\nElcom Group (CZ)\nEnvironnement SA (FR)\nHoneywell Specialty Chemicals (DE)\nIneos Fluor (UK)\nKatholieke Universiteit Leuven (BE)\nLGC Promochem (DE)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nSDS Solvants (FR)\nSanolabor (SI)\nSigma Aldrich Chemie (DE)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nUniversity Of Technology Vienna (AT)\nYa Kemia Oy \u2014 Sigma Aldrich (FI)\nANNEX IV\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:\nAirbus France (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nButterworth Laboratories (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\nAirbus France (FR)\nButterworth Laboratories (UK)\nIneos Fluor (UK)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nANNEX V\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:\nAcros Organics (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nAgfa-Gevaert (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBie & Berntsen (DK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBiosolve (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nButterworth Laboratories (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nFisher Scientific (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nHealth Protection Inspectorate-Laboratories (EE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nInstitut E. Malvoz (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nInstitut Scientifique de Service Public (ISSeP) (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nKatholieke Universiteit Leuven (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nLaboratoires S\u00e9rologiques (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMallinckrodt Baker (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMerck KGaA (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMikro + Polo (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nPanreac Qu\u00edmica (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nRohs Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSDS Solvants (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSanolabor d.d. (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Laborchemikalien (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nVWR I.S.A.S. (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nYA-Kemia Oy (FI)\nAcros Organics (BE)\nAgfa-Gevaert (BE)\nBie & Berntsen (DK)\nBiosolve (NL)\nButterworth Laboratories (UK)\nFisher Scientific (UK)\nHealth Protection Inspectorate-Laboratories (EE)\nInstitut E. Malvoz (BE)\nInstitut Scientifique de Service Public (ISSeP) (BE)\nKatholieke Universiteit Leuven (BE)\nLaboratoires S\u00e9rologiques (FR)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nRohs Chemie (DE)\nSDS Solvants (FR)\nSanolabor d.d. (SI)\nSigma Aldrich Chemie (DE)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nSigma Aldrich Laborchemikalien (DE)\nVWR I.S.A.S. (FR)\nYA-Kemia Oy (FI)\nANNEX VI\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:\nAcros Organics (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nAgfa-Gevaert (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBie & Berntsen (DK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nKatholieke Universiteit Leuven (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMallinckrodt Baker (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMikro + Polo (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nPanreac Qu\u00edmica (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSanolabor d.d. (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\nAcros Organics (BE)\nAgfa-Gevaert (BE)\nBie & Berntsen (DK)\nKatholieke Universiteit Leuven (BE)\nMallinckrodt Baker (NL)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nSanolabor d.d. (SI)\nSigma Aldrich Chemie (DE)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nANNEX VII\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:\nAcros Organics (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\nAcros Organics (BE)\nIneos Fluor (UK)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nANNEX VIII\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\nIneos Fluor (UK)\nSigma Aldrich Chemie (DE)\nSigma Aldrich Chimie (FR)\nANNEX IX\n(This Annex is not published because it contains confidential commercial information.)"}